In the pooled analysis of the DREAM and MENSA studies (37), a better response to treatment with the anti-IL5 mAb mepolizumab was observed in patients with severe asthma and BEC of ≥150 cells/μL in baseline. The gene discussed is IL5; the disease is asthma.